Who owns BELITE BIO, INC?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of BLTE from SEC Form 13F filings across 82 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 82 institutions disclosed 9.5M shares of BELITE BIO, INC worth $1.41B — about 23.8% of shares outstanding; the largest disclosed holder is Darwin Global Management, Ltd.. Source: SEC Form 13F filings, parsed by EvidInvest.
82
13F holders
$1.41B
value, 2026 filers
23.8%
of shares outstanding (9.5M sh)
24
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of BLTE's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Darwin Global Management, Ltd. | 3.1M | $456.6M | 12.1% | 7.7% | +0.6% |
| 2 | Paradigm Biocapital Advisors LP | 1.2M | $189.8M | 3.6% | 3.1% | +10.6% |
| 3 | RTW INVESTMENTS, LP | 715,332 | $110.2M | 0.9% | 1.8% | 0.0% |
| 4 | MILLENNIUM MANAGEMENT LLC | 494,564 | $76.2M | 0.0% | 1.2% | -13.2% |
| 5 | MAVERICK CAPITAL LTDNEW | 396,311 | $61.0M | 0.5% | 1% | new |
| 6 | EVENTIDE ASSET MANAGEMENT, LLC | 390,829 | $60.2M | 0.8% | 1% | +9.3% |
| 7 | DEERFIELD MANAGEMENT COMPANY, L.P. | 357,199 | $55.0M | 0.6% | 0.9% | +17.5% |
| 8 | Holocene Advisors, LP | 251,035 | $38.7M | 0.1% | 0.6% | -49.2% |
| 9 | Logos Global Management LPNEW | 250,000 | $38.5M | 1.7% | 0.6% | new |
| 10 | MORGAN STANLEY | 235,071 | $36.2M | 0.0% | 0.6% | +16.7% |
| 11 | UBS Group AG | 224,989 | $34.6M | 0.0% | 0.6% | -70.7% |
| 12 | CITADEL ADVISORS LLC | 186,168 | $28.7M | 0.0% | 0.5% | +9171.3% |
| 13 | GOLDMAN SACHS GROUP INC | 166,188 | $25.6M | 0.0% | 0.4% | +57.5% |
| 14 | Affinity Asset Advisors, LLC | 165,000 | $25.4M | 1.1% | 0.4% | +153.8% |
| 15 | MPM BIOIMPACT LLC | 137,208 | $21.1M | 1.3% | 0.3% | +55.8% |
| 16 | BANK OF AMERICA CORP /DE/ | 124,783 | $19.2M | 0.0% | 0.3% | +3202.9% |
| 17 | Patient Square Capital LP | 110,000 | $16.9M | 2.6% | 0.3% | -5.7% |
| 18 | Duquesne Family Office LLC | 106,100 | $16,338 | 0.3% | 0.3% | 0.0% |
| 19 | PRICE T ROWE ASSOCIATES INC /MD/ | 105,859 | $16,301 | 0.0% | 0.3% | -62.4% |
| 20 | JANE STREET GROUP, LLC | 65,801 | $10.1M | 0.0% | 0.2% | +438.4% |
| 21 | BNP PARIBAS FINANCIAL MARKETS | 57,125 | $8.8M | 0.0% | 0.1% | +75.6% |
| 22 | RENAISSANCE TECHNOLOGIES LLC | 55,763 | $8.6M | 0.0% | 0.1% | +7.2% |
| 23 | Point72 Asset Management, L.P.NEW | 51,186 | $7.9M | 0.0% | 0.1% | new |
| 24 | Soleus Capital Management, L.P.NEW | 50,524 | $7.8M | 0.3% | 0.1% | new |
| 25 | Trexquant Investment LP | 49,516 | $7.6M | 0.0% | 0.1% | +228.5% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.